Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2898
Title: | European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis | Authors: | Tonia, Thomy Powell, Zena Snijders, Deborah Song, Woo-Jung Zacharasiewicz, Angela Wilson, Christine Grimwood, Keith Kantar, Ahmad Chang, Anne Fortescue, Rebecca Alexopoulou, Efthymia Bell, Leanne Boyd, Jeanette Bush, Andrew Chalmers, James D. Hill, Adam T. Karadag, Bulent Midulla, Fabio McCallum, Gabrielle B. |
Issue Date: | 2021 | Source: | 58, (2), 2021 | Journal: | The European respiratory journal | Abstract: | There is increasing awareness of bronchiectasis in children and adolescents, a chronic pulmonary disorder associated with poor quality of life for the child/adolescent and their parents, recurrent exacerbations, and costs to the family and health systems. Optimal treatment improves clinical outcomes. Several national guidelines exist, but there are no international guidelines.The European Respiratory Society (ERS) Task Force for the management of paediatric bronchiectasis sought to identify evidence-based management (investigation and treatment) strategies. It used the ERS standardised methodology that included a systematic review of the literature and application of the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to define the quality of the evidence and level of recommendations.A multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, immunology, methodology, patient advocacy and parents of children/adolescents with bronchiectasis considered the most relevant clinical questions (for both clinicians and patients) related to managing paediatric bronchiectasis. 14 key clinical questions (seven PICO (Patient, Intervention, Comparison, Outcome) and seven narrative) were generated. The outcomes for each PICO were decided by voting by the panel and parent/patient advisory group.This guideline addresses the definition, diagnostic approach and antibiotic treatment of exacerbations, pathogen eradication, long-term antibiotic therapy, asthma-type therapies (inhaled corticosteroids and bronchodilators), mucoactive drugs, airway clearance, investigation of underlying causes of bronchiectasis, disease monitoring, factors to consider before surgical treatment, and the reversibility and prevention of bronchiectasis in children/adolescents. Benchmarking quality of care for children/adolescents with bronchiectasis to improve clinical outcomes and evidence gaps for future research could be based on these recommendations. (Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.)Date of Electronic Publication: 2021 Aug 26. Current Imprints: Publication: Sheffield, United Kingdom : European Respiratory Society; Original Imprints: Publication: Copenhagen : Published jointly by the Society and Munksgaard, 1988- | DOI: | 10.1183/13993003.02990-2020 | Resources: | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=33542057&site=ehost-live | Keywords: | Humans;Quality of Life;Bronchodilator Agents/therapeutic use;Adult;Adrenal Cortex Hormones/therapeutic use;Asthma*Bronchiectasis*/drug therapy;Bronchiectasis*/therapy;Child;Adolescent | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.